Delivery Order SPE2DB22D3016-SPE2DB25FAJG8

Award Date 1/6/25
Potential Completion Date 1/7/25
Potential Value $10K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $8,062.14 firm fixed-price delivery order is for the supply of 4566134271 - RECTIV 0.4% OINTMENT 30GM, with a completion date of October 18, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The $2,158.71 Firm Fixed Price Delivery Order is for the supply of 4564491281 RECTIV 0.4% OINTMENT 30GM, with a completion date of May 6, 2024. Amerisourcebergen Drug Corp holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, through December 31, 2025, to provide a comprehensive range of pharmaceutical...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical distribution company. The contract, valued at $5,997.88, is a firm fixed price delivery order for the provision of a pharmaceutical product, RECTIV 0.4% OINT 1S. The award has an ultimate completion date of May 8, 2024. Amerisourcebergen Drug Corp holds an indefinite delivery contract...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation for the supply of RECTIV 0.4% ointment in 30-gram tubes. The contract has a ceiling value of $5,703.19 and an ultimate completion date of August 21, 2024. It is a firm-fixed-price contract, with no set-aside designation. AmerisourceBergen, a major pharmaceutical distributor in the United States, will provide the requested pharmaceutical product to support federal healthcare...
The Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp for the supply of a pharmaceutical product, RECTIV 0.4% Ointment 30GM. The $3,705.96 contract has an ultimate completion date of August 1, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 between Amerisourcebergen and the DLA Troop Support Medical, which provides a comprehensive range of medical commodities to support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,137.00, is a Delivery Order with a Firm Fixed Price pricing type. It covers the procurement of a pharmaceutical product, "RECTIV 0.4% OINTMENT 30GM," with a completion date of December 9, 2024. The contract does not have a set-aside designation, indicating open competition....
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of 4564885184 RECTIV 0.4% OINTMENT 30GM to the Defense Logistics Agency (DLA). The contract is a firm fixed-price delivery order with a ceiling value of $1,958.04 and an ultimate completion date of June 13, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025, which serves as...
This contract award to Amerisourcebergen Drug Corp is for the supply of a pharmaceutical product, specifically RECTIV 0.4% OINTMENT 30GM, to the Defense Logistics Agency (DLA). The $1,434.09 fixed-price delivery order has a completion date of December 11, 2024. Amerisourcebergen is a major pharmaceutical distributor that holds a significant Indefinite Delivery Contract (IDC) valued at $999,999,999 with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This firm fixed price delivery order was awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4564033772 - RECTIV 0.4% OINT 1S, a specialty pharmaceutical product, with a ceiling value of $6,305.25. The award has an ultimate completion date of March 22, 2024. Amerisourcebergen Drug Corp serves as the prime contractor, delivering pharmaceutical products and medical supplies to support...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp Corporate Office Division. The contract is for the supply of RECTIV 0.4% OINTMENT 30GM, a pharmaceutical product, with a ceiling value of $1,182.51 and an ultimate completion date of August 21, 2024. The contract is a firm fixed-price delivery order and does not have a set-aside designation. Amerisourcebergen Drug Corp is a major supplier of...
  • SPE2DB22D3016
    Indefinite Delivery Contract
  • SPE2DB22D3016-SPE2DB25FAJG8
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,120.82, is for the delivery of RECTIV 0.4% ointment in 30 gram tubes. The contract does not have a set-aside designation, indicating open competition.

Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.

Generated 4/7/25, 10:50 AM